Resverlogix
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 4820 Richard Rd SW, Calgary, Alberta...Phone Number
(403) 254-9252Website
www.resverlogix.comRevenue
$6 MillionStock Symbol
RVXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Resverlogix
Founded in 2001, Resverlogix operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular, end-stage renal, chronic kidney, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. The company is headquartered in Calgary, Alberta, Canada.Explore more
Resverlogix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Resverlogix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Resverlogix had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Resverlogix launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Resverlogix is spiking on competitors!
Earning: See what the market has to say on Resverlogix recently announced quarterly report
Resverlogix, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Resverlogix
Funding: Get notified immidiatlly once Resverlogix has new funding data
Check if Resverlogix has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Resverlogix
Find more new buyers
Compare Similar Companies to Resverlogix
Compare insights from companies similar to Resverlogix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Resverlogix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Resverlogix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Resverlogix.
Resverlogix financials insights
Gather financial insights about Resverlogix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Unspecified
$1.8M
2014
Share Placement
$1.7M
Debt
$30M
2015
Share Placement
$36.6M
2017
Share Placement
$10M
Share Placement
$87M
2018
Debt
$30M
Share Placement
$10.3M
2019
Multiple Rounds
$32.2M
2021
Debt
$6M
Resverlogix Tech Stack
A closer look at the technologies used by Resverlogix
See more technologies
Most Recent Scoops
Left Company
Executive Move
Promotion
Executive Move
Funding
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Resverlogix News & Media
Resverlogix Announces Change to Its Board of Directors. - BioSpace
Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of DirectorsResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines."The beneficial effect of apabetalone highlighted in these models of facioscapulohumeral muscular dystrophy in combination with the impressive clinical and safety data in...Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology (ESC) reflect unmet need in the reduction of cardiovascular risk in patients with type 2 diabetes, and highlight the opportunity for apabetalone to benefit this high-risk population. New emphasis on combining multiple drugs with proven cardiovascular benefits mirrors...Resverlogix Announces Warrant Repricing and One-Year Extension
Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants") will be amended. Commencing on July 17, 2023, the exercise price of 24,508,489 Warrants (currently exercisable at prices ranging from $0.24 to $1.00 per share) will be reduced to $0.20 per share, and the expiry date of 10,713,505 of the Warrants that currently expire between April 26,
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Resverlogix
Sign Up For FreeTo access detailed company insights
Founded in 2001, Resverlogix operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular, end-stage renal, chronic kidney, neurodegenerative, fabry, peripheral artery,... Read More
